Skip to main content
Fuan Pharmaceutical （Group）co.,Ltd logo

Fuan Pharmaceutical （Group）co.,Ltd — Investor Relations & Filings

Ticker · 300194 ISIN · CNE1000011G4 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,014 across all filing types
Latest filing 2016-01-03 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 300194

About Fuan Pharmaceutical （Group）co.,Ltd

https://www.fapharm.com

Fuan Pharmaceutical (Group) Co., Ltd. is an integrated pharmaceutical enterprise specializing in the research, development, production, and distribution of a wide range of chemical drugs. The company operates across the entire value chain, encompassing pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and finished dosage forms. Its product portfolio primarily focuses on anti-infectives, particularly cephalosporins and penicillins, as well as treatments for cardiovascular diseases, oncology, and respiratory conditions. Fuan Pharmaceutical maintains large-scale manufacturing facilities and emphasizes technological innovation to support its diverse pipeline of generic and specialized medications. The group serves both domestic and international markets, providing essential healthcare solutions through its network of subsidiaries and specialized production bases.

Recent filings

Filing Released Lang Actions
北京永拓会计师事务所（特殊普通合伙）《关于对福安药业（集团）股份有限公司的重组问询函》的专项核查说明
Audit Report / Information Classification · 95% confidence The document is a detailed audit and verification report issued by an accounting firm (北京永拓会计师事务所) regarding a restructuring inquiry related to 福安药业（集团）股份有限公司. It contains extensive financial and legal analysis about share transfers, pricing, tax compliance, accounting treatment, and inter-company transactions. The document references specific accounting standards (e.g., 《企业会计准则第11号——股份支付》), tax laws, and provides detailed financial data and audit opinions. It is not a brief announcement or a presentation but a comprehensive audit-related report focusing on the restructuring inquiry and related financial and legal compliance. This fits the definition of an Audit Report / Information (AR) as it is a standalone audit report with applied accounting principles and verification results, distinct from a full Annual Report or other categories. 9M 2015
2016-01-03 Chinese
关于公司股票复牌的提示性公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (1223 characters) regarding the resumption of trading of the company's stock after a suspension due to a major asset restructuring. It references regulatory filings, stock suspension and resumption dates, and ongoing disclosure obligations related to a major asset acquisition. It does not contain financial statements or detailed financial data, nor is it a full report. It is an announcement about the stock resumption and related procedural updates, not the actual asset restructuring report or financial report. Therefore, it fits best as a Regulatory Filing (RNS) since it is a regulatory announcement about stock resumption and related disclosures.
2016-01-03 Chinese
关于发行股份及支付现金购买资产并募集配套资金暨关联交易报告书（草案）及其摘要修订的说明公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from 福安药业 (Fuan Pharmaceutical Group Co., Ltd.) regarding revisions and explanations related to a previously disclosed report titled 'Report on Issuance of Shares and Payment of Cash to Purchase Assets and Raise Supporting Funds and Related Party Transaction Report (Draft)'. It references a regulatory inquiry letter from the Shenzhen Stock Exchange and details responses and supplementary disclosures made to the report. The document is relatively short (3146 characters) and primarily serves as an explanatory announcement about amendments to a restructuring report rather than the report itself. It does not contain full financial statements or detailed financial data but rather explanations and clarifications related to a capital raising and asset acquisition transaction. Therefore, it fits best as a Capital/Financing Update (CAP) filing, which covers updates on company fundraising, financing activities, or capital structure changes.
2016-01-03 Chinese
关于深圳证券交易所《关于对福安药业（集团）股份有限公司的重组问询函》之回复
Capital/Financing Update Classification · 95% confidence The document is a detailed response to an inquiry letter from the Shenzhen Stock Exchange regarding a corporate restructuring involving 福安药业 (Fuan Pharmaceutical Group Co., Ltd.). It discusses in depth the background, pricing, tax compliance, and legal opinions related to a significant equity transfer and restructuring transaction. The text references a "重组问询函" (restructuring inquiry letter) and includes extensive financial, legal, and operational disclosures related to the transaction. It also includes independent financial advisor, lawyer, and accountant opinions, detailed shareholder and management information, and compliance with accounting standards. The document is lengthy (15,000 characters) and contains substantive financial and operational data related to a corporate restructuring and acquisition transaction. This matches the characteristics of a Capital/Financing Update (CAP) filing, as it provides updates on company fundraising, financing activities, and capital structure changes related to the acquisition and restructuring. It is not a full Annual Report (10-K), nor an Audit Report (AR), nor a simple announcement or certification. It is not a proxy statement or voting results. It is not a call transcript or earnings release. The document is focused on the restructuring transaction details and related financial and legal disclosures, consistent with Capital/Financing Update (CAP).
2016-01-03 Chinese
独立董事候选人声明（李群英）
Board/Management Information Classification · 95% confidence The document is a detailed declaration by an independent director candidate of a company, confirming compliance with various legal and regulatory requirements for the position. It includes statements about qualifications, independence, and absence of conflicts of interest. There is no financial data, no report of financial performance, no voting results, no management changes, no earnings information, and no mention of any report publication. The content is a formal declaration related to board/management matters, specifically about an independent director candidate's qualifications and independence. This fits best under Board/Management Information (MANG), which covers announcements related to changes or appointments in the company's board or senior management.
2015-12-24 Chinese
独立董事提名人声明
Board/Management Information Classification · 95% confidence The document is a formal statement by a nominator regarding the nomination of an independent director candidate for the company's board. It includes detailed declarations about the candidate's qualifications, compliance with regulatory requirements, and independence criteria. There is no financial data, no report of financial performance, no voting results, no management changes announcement, and no mention of any meeting materials or presentations. The document is a regulatory compliance statement related to board nominations, which fits best under Board/Management Information (MANG) as it concerns the nomination of a board member.
2015-12-24 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.